These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9818648)

  • 21. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis.
    Ertenli I; Kiraz S; Arici M; Haznedaroglu IC; Calgüneri M; Celik I; Kirazli S
    J Rheumatol; 1998 Jun; 25(6):1054-8. PubMed ID: 9632062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
    Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
    J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis.
    Hasegawa J; Nagashima M; Yamamoto M; Nishijima T; Katsumata S; Yoshino S
    J Rheumatol; 2003 Mar; 30(3):474-9. PubMed ID: 12610804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists.
    Paulus HE; Ramos B; Wong WK; Ahmed A; Bulpitt K; Park G; Sterz M; Clements P
    J Rheumatol; 1999 Nov; 26(11):2324-31. PubMed ID: 10555885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paraarticular trabecular bone loss at the ultradistal radius and increased arterial stiffening in postmenopausal patients with rheumatoid arthritis.
    Tanaka K; Inaba M; Goto H; Nagata-Sakurai M; Sakai S; Yamada S; Ueda M; Ishimura E; Nishizawa Y
    J Rheumatol; 2006 Apr; 33(4):652-8. PubMed ID: 16583470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study.
    Mielants H; Veys EM; Van der Straeten C; Ackerman C; Goemaere S
    J Rheumatol; 1991 Jul; 18(7):978-83. PubMed ID: 1920332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U; Teichmann J; Müller-Ladner U; Strunk J
    Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical relapse of rheumatoid arthritis (escape phenomenon) during low-dose methotrexate therapy].
    Suzuki Y; Noguchi A; Tajima C; Uehara R; Ide M; Ichikawa Y; Mizushima Y
    Ryumachi; 1998 Feb; 38(1):6-13. PubMed ID: 9564772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis.
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Gindzienska-Sieskiewicz E; Chwiecko J
    J Rheumatol; 2006 Aug; 33(8):1523-9. PubMed ID: 16881109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone alkaline phosphatase in rheumatoid arthritis: a longitudinal study.
    Beyeler C; Banks R; Thompson D; Forbes MA; Cooper EH; Bird HA
    J Rheumatol; 1996 Feb; 23(2):241-4. PubMed ID: 8882026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of longterm therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CD8+ T lymphocytes of patients with rheumatoid arthritis.
    Schuerwegh AJ; van Offel JF; Bridts CH; Stevens WJ; De Clerck LS
    J Rheumatol; 2001 Aug; 28(8):1793-9. PubMed ID: 11508581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short term effects of low dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis.
    Segal R; Caspi D; Tishler M; Wigler I; Yaron M
    J Rheumatol; 1989 Jul; 16(7):914-7. PubMed ID: 2504917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis.
    Benito-Garcia E; Heller JE; Chibnik LB; Maher NE; Matthews HM; Bilics JA; Weinblatt ME; Shadick NA
    J Rheumatol; 2006 Jul; 33(7):1275-81. PubMed ID: 16821266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Boersma A; Marchandise X; Delcambre B
    J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
    Woo P; Southwood TR; Prieur AM; Doré CJ; Grainger J; David J; Ryder C; Hasson N; Hall A; Lemelle I
    Arthritis Rheum; 2000 Aug; 43(8):1849-57. PubMed ID: 10943876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
    Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ
    Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.